Levilimab
From Wikipedia, the free encyclopedia
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Levilimab is an anti-IL-6 monoclonal antibody initially developed to treat rheumatoid arthritis. In 2020, it was approved as a treatment for COVID-19 in Russia.[1][2][3]
